Delveinsight

AUGUST 2, 2020

Cachexia is observed as a result of underlying diseases, including cancer, AIDS, tuberculosis, chronic heart failure, hormonal deficiency, and others. NGM120 is a first-in-class antagonistic antibody, which binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15).

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

APRIL 28, 2022

Despite the inherent difficulties, major pharma companies do take aim at rare diseases, usually with dedicated units focusing on clusters of rare diseases that afflict the same part of the body. How big pharma tackles rare diseases. It’s a different business model, if you will,” Miquel said. “So So that is the trick.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

pharmaphorum

DECEMBER 23, 2020

The company’s menopause drug NT-814 is heading for phase 3 development in 2021 following a mid-stage trial readout. NT-814 is a non-hormonal drug that works on the neurokinin (NK) 1,3 receptor antagonist, thus treating the vasomotor symptoms associated with the menopause. Rare disease progress.

Marketing 78

Marketing Gene Silencing Gene Drugs 78

Delveinsight

AUGUST 6, 2020

Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood. Pharma companies like Alnylam Pharmaceuticals , Ionis Pharmaceuticals , Eidos Therapeutics, and many others are providing the thrust to the Hereditary transthyretin amyloidosis market forward.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52

Roots Analysis

MAY 21, 2024

Due to which, several big pharma companies and other industry stakeholders are actively contributing towards development of protein degradation therapies and technologies, contributing towards growth of targeted protein degradation market.

Protein 40

Protein Marketing Development Antibody 40

Delveinsight

DECEMBER 2, 2020

Even after several years of research, exact causes of Rheumatoid Arthritis are unknown, but some factors are believed that trigger the immune system to mistakenly send antibodies to attack the joints and the tissues surrounding them; which in turn results in pain and inflammation. These antibodies are signs of hyperactive immunity.

Marketing 60

Marketing Hormones Antibody Development 60

The Pharma Data

OCTOBER 14, 2020

VBL Therapeutics – The European Patent Office granted a patent to Israel-based VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. VBL is currently advancing its lead anti-MOSPD2 candidate through IND-enabling studies.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52